In another severe setback for the application of immunotherapy in the treatment of advanced prostate cancer, Cell Genenesys has announced the early termination of the Phase III VITAL-2 clinical trial … more →
THE "NEW" PROSTATE CANCER INFOLINKSitemaster wrote 10 months ago: In another severe setback for the application of immunotherapy in the treatment of advanced prostate … more →